Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. Nathan Lack

Nathan Lack

Assistant Professor
Academic Appointment
Assistant Professor
Research Focus
Kidneys and Urinary System Cancers
Contact Info
nathan.lack@ubc.ca
lack_lab
nathan-lack-24b8a623/

Biography

Dr. Nathan Lack is a senior research scientist at the Vancouver Prostate Centre and an assistant professor in the Department of Urologic Sciences at the University of British Columbia. He obtained a PhD in pharmacology from the University of Oxford in 2009 followed by a postdoctoral fellowship at the Vancouver Prostate Centre with Dr. Emma Guns and Professor Paul Rennie. Dr. Lack became an assistant professor at Koç University’s School of Medicine in 2011 and was awarded associate professorship in 2015. In addition to his academic research, he previously worked for AnorMED Inc., where he was involved in the development of the FDA-approved therapeutic Plerixafor.

Dr. Lack’s laboratory is focused on identifying and characterizing novel drug targets to treat aggressive late-stage prostate cancer by utilizing advanced functional genomics techniques in combination with classical pharmacology. In addition to extensive publications, the research from his group has identified several compounds that have been licenced and progressed to clinical development. Dr. Lack has received numerous awards for his work, including Vancouver Coast Health Research Institute’s Rising Star Award and the prestigious TÜBA-GEBIP, which is given to the best young scientists in Turkey.

News and Awards

Mapping the driver of prostate cancer

Apr 20, 2022

Publications

  • Genome biology -

    Functional mapping of androgen receptor enhancer activity.

    Huang CF, Lingadahalli S, Morova T, Ozturan D, Hu E, Yu IPL, Linder S, Hoogstraat M, Stelloo S, Sar F, van der Poel H, Altintas UB, Saffarzadeh M, Le Bihan S, McConeghy B, Gokbayrak B, Feng FY, Gleave ME, Bergman AM, Collins C, Hach F, Zwart W, Emberly E, Lack NA
  • Journal of cell science -

    DNA binding alters ARv7 dimer interactions.

    Özgün F, Kaya Z, Morova T, Geverts B, Abraham TE, Houtsmuller AB, van Royen ME, Lack NA
  • Nature communications -

    Androgen receptor-binding sites are highly mutated in prostate cancer.

    Morova T, McNeill DR, Lallous N, Gönen M, Dalal K, Wilson DM, Gürsoy A, Keskin Ö, Lack NA
  • Cancers -

    Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer.

    Ban F, Leblanc E, Cavga AD, Huang CF, Flory MR, Zhang F, Chang MEK, Morin H, Lallous N, Singh K, Gleave ME, Mohammed H, Rennie PS, Lack NA, Cherkasov A
  • Journal of medicinal chemistry -

    Development of 2-(5,6,7-Trifluoro-1-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.

    Leblanc E, Ban F, Cavga AD, Lawn S, Huang CF, Mohan S, Chang MEK, Flory MR, Ghaidi F, Lingadahalli S, Chen G, Yu IPL, Morin H, Lallous N, Gleave ME, Mohammed H, Young RN, Rennie PS, Lack NA, Cherkasov A
  • The Prostate -

    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.

    Şeref C, Acar Ö, Kılıç M, Vural M, Sağlıcan Y, Saraç H, Coşkun B, İnce Ü, Esen T, Lack NA
Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy